samedan logo
 
 
 
spacer
home > ebr > autumn 2007 > mass spectrometry in peptide biomarker discovery and peptidomics
PUBLICATIONS
European Biopharmaceutical Review

Mass Spectrometry in Peptide Biomarker Discovery and Peptidomics

Rodion Demin at DIGILAB BioVisioN GmbH discusses the requirements of peptidomics technology related to mass spectrometry and differences compared with proteomics in biomarker discovery

Biomarkers are defined as characteristics that are objectively measured and evaluated as indicators of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention (1). Various studies showed that native peptides from bodily fluids such as blood, urine or cerebrospinal fluid, as well as cells or tissues, could act as biomarkers and be used for diagnostic purposes or for monitoring disease stages (2,3).

Peptides are products of proteolytical protein processing, and their biochemistry reflects the changes of the biological state of any living organism. These changes are indicated by the presence or absence of specific peptides or a significant change in their abundance in biological samples. Furthermore, various peptides have biological activity (such as regulatory function) or are associated with different diseases, so that the probability of finding relevant biomarkers in peptidomes is high (see Figure 1).

The advantage of a biomarker discovery by means of peptidomics is largely due to the high accessibility of biological source material, especially of bodily fluids. However, these samples have extremely high complexity and quantitative diversity. Peptides with biological activity are mainly present in a very low concentration. An additional challenge is that ongoing enzymatic processes or coagulation in the cases of blood samples can affect the peptidome by activation of degradation processes (4,5).

For peptide biomarker discovery, a comprehensive peptide profiling for the identification of biomarker candidates and determination of their amino acid sequence is necessary. Mass spectrometry, such as matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI) techniques for the analysis of intact peptides and protein digests has evolved as a powerful key technology in this area. Hence, the understanding of the utility of mass spectrometry not as a standalone technique but as part of a highly complex discovery process, which starts with the collection of clinical sample material and ends with the biological interpretation of biomarker sequence information, is very important. This understanding avoids failures and minimises and controls the influences of analytical equipment and sample material handling (6).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Rodion Demin studied Chemistry and received his PhD in Bio-Organic Chemistry at Humboldt University in Berlin, Germany. He has worked in clinical research group Tumor Immunology at the Charité in Berlin on the identification of immunologically active peptides and development of new methods for peptide sequencing by mass spectrometry. Since 2006, he has been head of the mass spectrometry department at DIGILAB BioVisioN GmbH.
spacer
Rodion Demin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Schrödinger Announces Acquisition of XTAL BioStructures, Inc.

NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the acquisition of XTAL BioStructures, Inc., a private company based in the Greater Boston area that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, to the pharmaceutical and biotechnology industries.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement